Slow Start For New Novartis Heart Failure Drug Entresto

Initial sales of Entresto (the combination of sacubitril and valsartan, formerly known as LCZ696) have been slow. In the first few months after its approval in July the drug only had $16 million in sales, the drug’s manufacturer, Novartis, reported last week during its quarterly earnings report. The novel heart failure drug is widely expected to be...Click here to continue reading...

Source: CardioBrief - November 2, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Entresto guidelines LCZ 696 Medicare Novartis Source Type: blogs